For the treatment of unresectable or metastatic melanoma, consider

Viktig sikkerhets- og forskrivningsinformasjon

Indication

Opdualag^®(nivolumab and relatlimab) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.

PD-L1 testing

Patients should be selected for treatment with Opdualag based on the tumour expression of
PD-L1 confirmed by a validated test.

Reference: 

1. Opdualag SmPC